{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:14:34Z","timestamp":1770977674447,"version":"3.50.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1097\/jcp.0b013e3182917f3f","type":"journal-article","created":{"date-parts":[[2013,4,20]],"date-time":"2013-04-20T14:15:49Z","timestamp":1366467349000},"page":"425-431","source":"Crossref","is-referenced-by-count":17,"title":["Risk for Adverse Events and Discontinuation Due To Adverse Events of Ziprasidone Monotherapy Relative to Placebo in the Acute Treatment of Bipolar Depression, Mania, and Schizophrenia"],"prefix":"10.1097","volume":"33","author":[{"given":"Keming","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Pappadopulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onur N.","family":"Karayal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheela","family":"Kolluri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph R.","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"suppl 4","key":"R1-23-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4088\/JCP.7090su1cj","article-title":"The expert consensus guideline series: adherenceproblems in patients with serious and persistent mental illness.","volume":"70","author":"Velligan","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"R2-23-20210128","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1017\/S1461145709990344","article-title":"Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis.","volume":"13","author":"Cruz","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"R3-23-20210128","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4088\/JCP.v69n0217","article-title":"A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence.","volume":"69","author":"Gao","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R4-23-20210128","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/JCP.0b013e318166c4d5","article-title":"Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review.","volume":"28","author":"Gao","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"R5-23-20210128","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.4088\/JCP.09r05535gre","article-title":"Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics.","volume":"72","author":"Gao","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"R6-23-20210128","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1017\/S146114571000101X","article-title":"Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder.","volume":"14","author":"Wang","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"R9-23-20210128","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.4088\/JCP.09m05934","article-title":"Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.","volume":"72","author":"Sachs","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"R10-23-20210128","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","article-title":"Ziprasidone 80 mgday and 160 mgday in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.","volume":"20","author":"Daniel","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"R11-23-20210128","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00004714-200102000-00007","article-title":"Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies.","volume":"21","author":"Keck","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"R12-23-20210128","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1176\/appi.ajp.160.4.741","article-title":"Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.","volume":"160","author":"Keck","year":"2003","journal-title":"Am J Psychiatry"},{"key":"R13-23-20210128","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s002130050755","article-title":"Ziprasidone 40 and 120 mgday in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial.","volume":"140","author":"Keck","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"R14-23-20210128","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/01.jcp.0000169068.34322.70","article-title":"Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial.","volume":"25","author":"Potkin","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"R16-23-20210128","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/0269881108099418","article-title":"Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study.","volume":"24","author":"Vieta","year":"2010","journal-title":"J Psychopharmacol"},{"key":"R17-23-20210128","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.biopsych.2005.09.014","article-title":"Size of treatment effects and their importance to clinical research and practice.","volume":"59","author":"Kraemer","year":"2006","journal-title":"Biol Psychiatry"},{"key":"R18-23-20210128","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.schres.2009.03.009","article-title":"Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials.","volume":"111","author":"Citrome","year":"2009","journal-title":"Schizophr Res"},{"key":"R19-23-20210128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.schres.2009.09.023","article-title":"Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder.","volume":"115","author":"Citrome","year":"2009","journal-title":"Schizophr Res"},{"issue":"suppl 3","key":"R20-23-20210128","first-page":"38","article-title":"Side effects as influencers of treatment outcome.","volume":"69","author":"Sharif","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R21-23-20210128","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis.","volume":"156","author":"Allison","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R22-23-20210128","first-page":"CD006627","article-title":"Ziprasidone versus other atypical antipsychotics for schizophrenia.","volume":"4","author":"Komossa","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"R23-23-20210128","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.schres.2008.09.025","article-title":"Weight effects associated with antipsychotics: a comprehensive database analysis.","volume":"110","author":"Parsons","year":"2009","journal-title":"Schizophr Res"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e3182917f3f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T06:19:10Z","timestamp":1688192350000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201306000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3182917f3f","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}